Inactivating mutations of the SOST (sclerostin) gene are associated with overgrowth and sclerosis of the skeleton. To determine mechanisms by which increased amounts of calcium and phosphorus are accreted to enable enhanced bone mineralization in the absence of sclerostin, we measured concentrations of calciotropic and phosphaturic hormones, and urine and serum calcium and inorganic phosphorus in mice in which the sclerostin (sost) gene was replaced by the β-D-galactosidase (lacZ) gene in the germ line. Knockout (KO) (sost −/− ) mice had increased bone mineral density and content, increased cortical and trabecular bone thickness, and greater net bone formation as a result of increased osteoblast and decreased osteoclast surfaces compared with wild-type (WT) mice. β-Galactosidase activity was detected in osteocytes of sost KO mice but was undetectable in WT mice. Eight-week-old, male sost KO mice had increased serum 1α,25-dihydroxyvitamin D, decreased 24,25-dihydroxyvitamin D, decreased intact fibroblast growth factor 23, and elevated inorganic phosphorus concentrations compared with age-matched WT mice. 25-Hydroxyvitamin D 1α-hydroxylase cytochrome P450 (cyp27B1) mRNA was increased in kidneys of sost KO mice compared with WT mice. Treatment of cultured proximal tubule cells with mouse recombinant sclerostin decreased cyp27B1 mRNA transcripts. Urinary calcium and renal fractional excretion of calcium were decreased in sost KO mice compared with WT mice. Sost KO and WT mice had similar serum calcium and parathyroid hormone concentrations. The data show that sclerostin not only alters bone mineralization, but also influences mineral metabolism by altering concentrations of hormones that regulate mineral accretion. S clerostin, an osteocyte-derived, secreted, cystine-knot protein inhibits bone formation by interacting with and altering the activity of bone morphogenetic proteins (BMPs), low-density lipoprotein-receptor-related protein 5 (LRP 5/6), cysteine-rich protein 61, the receptor tyrosine kinase v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (erb B3), among other proteins (1-12). Inactivating mutations in the human sclerostin gene (SOST) are associated with sclerosteosis (Mendelian Inheritance in Man, MIM 269500) or van Buchem disease (MIM 239100) (6), both of which are characterized by progressive overgrowth and sclerosis of the axial and appendicular skeleton and an increase in bone mineral density (6, 13, 14) . These results are supported by data from sost knockout mice, which have markedly increased bone density (15-17).
Inactivating mutations of the SOST (sclerostin) gene are associated with overgrowth and sclerosis of the skeleton. To determine mechanisms by which increased amounts of calcium and phosphorus are accreted to enable enhanced bone mineralization in the absence of sclerostin, we measured concentrations of calciotropic and phosphaturic hormones, and urine and serum calcium and inorganic phosphorus in mice in which the sclerostin (sost) gene was replaced by the β-D-galactosidase (lacZ) gene in the germ line. Knockout (KO) (sost −/− ) mice had increased bone mineral density and content, increased cortical and trabecular bone thickness, and greater net bone formation as a result of increased osteoblast and decreased osteoclast surfaces compared with wild-type (WT) mice. β-Galactosidase activity was detected in osteocytes of sost KO mice but was undetectable in WT mice. Eight-week-old, male sost KO mice had increased serum 1α,25-dihydroxyvitamin D, decreased 24,25-dihydroxyvitamin D, decreased intact fibroblast growth factor 23, and elevated inorganic phosphorus concentrations compared with age-matched WT mice. 25-Hydroxyvitamin D 1α-hydroxylase cytochrome P450 (cyp27B1) mRNA was increased in kidneys of sost KO mice compared with WT mice. Treatment of cultured proximal tubule cells with mouse recombinant sclerostin decreased cyp27B1 mRNA transcripts. Urinary calcium and renal fractional excretion of calcium were decreased in sost KO mice compared with WT mice. Sost KO and WT mice had similar serum calcium and parathyroid hormone concentrations. The data show that sclerostin not only alters bone mineralization, but also influences mineral metabolism by altering concentrations of hormones that regulate mineral accretion.
S
clerostin, an osteocyte-derived, secreted, cystine-knot protein inhibits bone formation by interacting with and altering the activity of bone morphogenetic proteins (BMPs), low-density lipoprotein-receptor-related protein 5 (LRP 5/6), cysteine-rich protein 61, the receptor tyrosine kinase v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (erb B3), among other proteins (1-12). Inactivating mutations in the human sclerostin gene (SOST) are associated with sclerosteosis (Mendelian Inheritance in Man, MIM 269500) or van Buchem disease (MIM 239100) (6) , both of which are characterized by progressive overgrowth and sclerosis of the axial and appendicular skeleton and an increase in bone mineral density (6, 13, 14) . These results are supported by data from sost knockout mice, which have markedly increased bone density (15) (16) (17) .
The physiological adaptations that occur in human sclerosteosis and mouse models of the disease that permit the increased accretion of calcium (Ca) and phosphorus (P) required for bone formation are unknown. For example, it is unknown whether sclerostin influences vitamin D metabolite concentrations, the concentrations of phosphaturic peptides such as fibroblast growth factor 23 (FGF-23), and the renal handling of calcium and phosphorus. It is important to understand the adaptations that occur in the kidney and intestine, which allow additional amounts of Ca and P to be retained in humans and mice lacking the SOST/sost gene, because such information will provide insights into previously unrecognized mechanisms by which Ca and P homeostasis are maintained. To address this issue, we generated a mouse model in which the sost gene was deleted in the germ line. We measured concentrations of serum minerals, calciumand phosphorus-regulating hormones and peptides, and urinary Ca and P excretion. We demonstrate that in sost KO mice, serum concentrations of the calcium-regulating sterol, 1α,25-dihydroxyvitamin D (1α,25(OH) 2 D) are increased and concentrations of the phosphate-regulating peptide, FGF-23, are diminished compared with concentrations present in WT mice. Serum inorganic phosphorus concentrations are elevated. Urinary excretion of calcium is reduced. These hormonal adaptations allow enhanced accretion of Ca and P into the skeleton of the sost KO mouse and point to unique effects of sclerostin on 1α,25 (OH) 2 D and 24,25(OH) 2 D production and FGF-23 formation.
Results
Heterozygous mice in which one copy of the sost gene was replaced with a β-galactosidase-human ubiquitin C promoter/T7 promoter (hUBC/em7)-neomycin-polyA cassette (Fig. 1A) were fertile, had litters of normal size (6-9 pups per litter), and produced offspring in the appropriate Mendelian ratio. The size and growth rate of sost −/− (KO) and sost +/+ (WT) mice were similar at 8 wk of age. The genotype of the animals was established by PCR analysis of genomic DNA and by the presence of β-galactosidase staining in the skeleton of sost KO mice (Fig. 1) . Osteocytes in sost KO mice displayed an intense blue color when exposed to the chromogenic substrate, 5-bromo-4-chloro-3-indolyl-β-galactopyranoside, indicating the presence of galactosidase activity encoded by the β-Dgalactosidase (lacZ) gene (Fig. 1C, Right) , whereas osteocytes in WT mice did not display galactosidase activity (Fig. 1C, Left) . Galactosidase activity was not detected in the liver, intestine, or kidney tubules of sost KO mice. Serum sclerostin concentrations were undetectable in KO (sost −/− ) mice but were clearly detected in WT (sost +/+ ) mice (618 ± 57.1 pg/mL, mean ± SEM). Sost KO mice displayed a striking sclerotic skeletal phenotype. At 8 wk age, bone mineral density and content in the whole body (minus head), spine, and femur were increased in sost KO mice compared with WT mice as assessed by dual energy X-ray absorptiometry (Table 1) . Microcomputed tomography (microCT) of trabecular bone in the distal femur showed statistically significant increases in trabecular bone volume fraction and trabecular thickness, but no change in trabecular number, separation, or connectivity (Table 1) . A representative image of trabecular bone from the distal femur is shown in Fig. 2A , Left, WT; Right, sost KO. MicroCT of cortical bone in the femur showed statistically significant increases in cortical bone area, bone cross-sectional area, and cortical bone thickness in sost KO versus WT mice (Table 1) , whereas medullary volume fraction was decreased, indicating a relative decrease in the proportion of the marrow cavity. A representative image of cortical bone from the midshaft of the femur is shown in Fig. 2B , Left, WT; Right, sost KO.
Quantitative bone histomorphometry (Table 2) at 8 wk of age shows an increase in osteoblast surface in sost KO mice. Osteoclast surface and number were decreased in sost KO compared with WT mice (Table 2 ). Dynamic fluorochrome measurements showed an increase in the number of double-labeled surfaces/ bone surface, mineralizing surface/bone surface, mineral apposition rate, and bone formation rate/tissue volume in sost KO compared with WT mice (Table 2 and Fig. 2C ). The increase in bone formation was supported by measurement of a bone formation rate index (ratio of serum procollagen type I N propeptide (P1NP) to tartrate-resistant acid phosphatase 5B (TRAcP5B), (KO 23.18 ± 3.17 versus WT 13.08 ± 0.69 ng/mU, P = 0.035). At 16 wk of age, microCT and dynamic histomorphometry indices show continued and increased deposition of bone, increased osteoblast numbers, and reduced osteoclast numbers in sost KO mice compared with WT mice (Tables S1 and S2 and Fig. S1 ).
We next assessed the levels of a variety of serum markers relating to mineral homeostasis. As expected, serum sclerostin was undetectable in sost KO mice but was clearly detected in WT mice (618 ± 57.1 pg/mL). Serum 1α,25(OH) 2 D concentrations measured by liquid chromatography-mass spectrometry were ∼12 pg/mL (∼30%) higher in sost KO versus WT mice (39.1 ± 3.0 versus 26.9 ± 1.8 pg/mL, mean ± SEM, P = 0.0018) (Fig. 3A) . In contrast, serum 24,25(OH) 2 D concentrations were significantly lower (∼30%) in sost KO versus WT mice (7.44 ± 0.32 versus 10.59 ± 0.68 ng/mL, P = 0.003) (Fig. 3B) . Serum concentrations of the phosphaturic factor, intact FGF-23, were significantly lower in sost KO versus WT mice (65.45 ± 6.18 versus 151.74 ± 11.74 pg/mL, P < 0.001) (Fig. 3C) . Consistent with changes in intact FGF-23 concentrations, serum P levels were significantly elevated in sost KO versus WT mice (7.44 ± 0.26 versus 6.68 ± 0.19 mg/dL, P = 0.024) (Fig. 3D ). Serum Ca concentrations were similar in sost KO and WT mice (8.38 ± 0.18 versus 8.26 ± 0.11 mg/dL, P = not significant (NS) (Fig. 3E) . Concentrations of intact parathyroid hormone (PTH) were also similar in sost KO versus WT mice (209.5 ± 25.2 versus 223.6 ± 50.9 pg/mL, P = NS) (Fig. 3F) .
Excretion of urinary Ca and P in sost KO and WT mice was assessed by collecting urine for a period of 24 h. Urinary Ca excretion was significantly reduced in sost KO versus WT mice (0.0158 ± 0.0015 versus 0.0288 ± 0.00257 mg/24 h, P < 0.001) (Fig. 4A ). Glomerular filtration rate was similar in the two groups of mice (196.6 ± 16.36 versus 214.79 ± 20.18 μL/min, P = not significant). The fractional excretion of Ca was reduced in sost KO compared with WT mice (0.074 ± 0.009% versus 0.13 ± 0.022%, P = 0.024) (Fig. 4B ). Urinary P excretion and the fractional excretion of P were similar in sost KO and WT mice (P = not significant) ( Fig. 4 C and D) . Together these data demonstrate that sclerostin deletion influences mineral metabolism by enhancing accretion of Ca and P.
To assess the mechanism by which sclerostin influences vitamin D metabolism, we measured 25-hydroxyvitamin D 1α-hydroxylase cytochrome P450 (cyp27b1) mRNA concentrations from kidneys of 8-wk-old mice, and from proximal tubular cells treated with recombinant mouse sclerostin. Cyp27b1 mRNA concentrations were increased in the kidneys of sost KO mice compared with WT mice [KO 1.234 ± 0.179 (n = 9) versus WT 0.789 ± 0.109 (n = 7) relative units (RU), P = 0.06]. In proximal tubular cells treated with 0.5 μg/mL of sclerostin for 24 h, cyp27b1 mRNA transcripts were decreased in recombinant sclerostin- treated cells compared with vehicle controls (treated 0.365 ± 0.0569 versus vehicle 1.0324 ± 0.0948 (RU), P = < 0.001).
Discussion
We developed a sclerostin KO (sost −/− ) mouse to delineate the influence of sclerostin on systemic mineral metabolism and to specifically address how, in the absence of sclerostin, accretion of sufficient amounts of calcium and phosphorus occur to facilitate enhanced bone formation. Consistent with previous reports, our sost KO mice demonstrated increased appendicular and axial bone mineral density and bone mineral content as assessed by dual energy X-ray absorptiometry. MicroCT confirmed striking increases in bone mass, cortical bone area, cortical bone thickness, decreases in the proportion of the medullary canal, and increased trabecular bone mass. Quantitative histomorphometry indicated the increase in bone mass resulted from a net increase in bone formation. Interestingly, bone remodeling appeared to be unbalanced in the sost KO mice, favoring formation over resorption, as seen both histologically and via serum markers (P1NP and TRAcP5B) of bone turnover. Osteoblast surface and double-labeled surface were both increased in sost KO mice, whereas osteoclast surface was reduced. In 16-wk-old mice, differences in bone assessed by microCT in sost KO relative to WT mice are more pronounced. Bone histomorphometry shows an increase in osteoblast numbers on trabecular surfaces and a trend toward a decrease in osteoclast numbers. In sost KO mice, lacZ activity was observed in the calvarial, limb, and axial skeleton. Our data are consistent with those published regarding other mouse models in which the sost gene was deleted in the germ line (15) (16) (17) .
We next addressed the mechanisms that allow a positive mineral balance to occur in the absence of sclerostin. Calcium and P absorption in the intestine and Ca and P reabsorption in the kidney regulate overall mineral balance (18) (19) (20) (21) (22) (23) . Active Ca and P absorption in the intestine are regulated by the vitamin D metabolite, 1α,25(OH) 2 D (20, 24, 25) . We observed significantly higher concentrations of 1α,25(OH) 2 D in sost KO mice. This increase in 1α,25(OH) 2 D concentrations is predicted to increase intestinal Ca and P absorption in the intestine and Ca and P reabsorption in the kidney, resulting in a more positive Ca and P balance required for enhanced skeletal mineral accretion.
The mechanism by which 1α,25(OH) 2 D concentrations are increased is likely to be due to an increase in the formation of 1α,25(OH) 2 D by the renal 25-hydroxyvitamin D 1α-hydroxylase. This is supported by the increased concentrations of renal cyp27B1 mRNA in sost KO mice compared with WT mice. This enzyme is regulated by PTH, FGF-23, and by the concentration of serum P (24, (26) (27) (28) (29) (30) (31) . In sost KO mice, FGF-23 concentrations are reduced compared with those found in WT mice. FGF-23 is known to inhibit 25-hydoxyvitamin D 1α-hydroxylase activity (31) . Thus, it is likely that the decrement in serum FGF-23 concentrations is responsible for the increase in 1α,25(OH) 2 D seen in sost KO mice. A direct effect of sclerostin on 25-hydroxyvitamin D 1α-hydroxylase activity is also likely as the treatment of murine proximal tubular cells with recombinant mouse sclerostin is associated with a decrease in cyp27B1 mRNA concentrations. The absence of galactosidase activity in kidney tubules makes it unlikely that renal sclerostin production is playing a role in regulating hydroxylase activity. PTH regulates 25-hydroxyvitamin D 1α-hydroxylase activity. Serum PTH concentrations are normal in sost KO mice and are not elevated relative to those seen in WT mice. Thus, PTH is not likely to be the mediator of increased 1α,25(OH) 2 D concentrations. However, it is plausible that increased serum PTH concentrations may be present at earlier stages of development and could account for increased cyp27b1 mRNA expression. Low serum P is known to stimulate 25-hydroxyvitamin D 1α-hydroxylase activity. In sost KO mice serum P concentrations are elevated, most likely secondary to reduced serum FGF-23, and hence the increase in serum 1α,25(OH) 2 D seen in sost KO mice cannot be attributed to changes in serum P.
The precise mechanism for reduced FGF-23 concentrations in sost KO mice is not known. However, both sclerostin and FGF-23 are produced in osteocytes (1, 2, 32-35), and it is plausible that in the absence of sclerostin, FGF-23 production is diminished. We have recently shown that sclerostin interacts with phex (a protein encoded by the phosphate regulating gene with homologies to endopeptidases on the X chromosome) ( Reduced urinary Ca excretion could also account for increased Ca retention. Because serum Ca and glomerular filtration rates are normal in sost KO mice, reduced filtered load cannot account for the change in urinary Ca excretion. PTH, which is known to influence urinary Ca excretion is similar in sost KO and WT mice and thus changes in PTH are unlikely to account for the change in urinary Ca reabsorption (38, 39) . The increased 1α,25(OH) 2 D concentrations observed in sost KO mice could account for the reduction in urinary Ca seen in these animals (22) . A direct influence of sclerostin on urinary Ca excretion cannot be discounted. As noted earlier, the absence of galactosidase activity in tubules makes it unlikely that local renal sclerostin production is playing a role in regulating Ca reabsorption in the kidney. Interestingly, despite decreases in serum FGF-23 seen in sost KO mice, urinary P excretion and the urinary fractional excretion of P are similar in sost KO and WT mice.
The lack of elevated serum Ca concentrations in sost KO mice despite increases in 1α,25(OH) 2 D concentrations and a reduction in urinary Ca excretion could be due to enhanced skeletal uptake of Ca required for increased bone formation.
In 
Materials and Methods
Animal studies were approved by the Mayo Clinic Institutional Animal Care and Use Committee. Seventy-two hours later, the mice received an i.p. injection of 5 IU of human chorionic gonadotrophin. Frozen sperm from a sost +/− mouse were thawed at room temperature until all liquid nitrogen had dispersed. Sperm were then maintained for another 2 min at 37°C and centrifuged at 600 × g for 5 min. The supernatant was removed and sperm were resuspended in 100 μL human tubal fluid (HTF) medium and incubated at 37°C for 10 min. Another 50 μL of HTF medium was added to the fertilization drop. Fourteen hours post-hCG injection, super ovulating females were killed and oviducts were removed and transferred to HTF medium at room temperature. The cumulus masses containing ova were isolated and transferred to HTF medium. Cumulus masses were transferred to HTF medium containing sperm and left for 4 h at 37°C. The eggs were collected and washed through several changes of simplex optimized medium (KSOM) buffer and left in culture dishes containing KSOM overnight at 37°C. Fertilized ova were implanted into pseudopregnant imprinting control region female mice to obtain offspring that were bred through several generations to obtain sost +/− mice on a C57BL/ 6 background. Mice were genotyped using appropriate primers. The first primer pair amplifies 193 bp of the WT allele from the first exon of sclerostin. The sequences of the primers are: Fwd WT1: 5′-CCGTGCCTCATCTGCCTACTTG-3′ and Rev WT2: 5′-TGGCGTCATAGGGATGGTG-3′. The second primer pair amplifies 496 bp of the mutant allele at the 3′ end of the ablation cassette through the genomic region 3′ of the sclerostin stop codon. The primer sequences are: Fwd KO1: 5′-GCAGCCTCTGTTCCACATACACTTCA-3′ and Rev KO2: 5′-GTCAGGGTCAGAAACCCTATCTAGCC-3′).
Assessment of Bone Mineral Density via Dual X-Ray Absorptiometry. Bone mineral density was assessed using previously published methods and a Lunar PIXImus (Lunar) bone mineral densitometer (42) . Specific analyses were conducted using software version 1.44.005.
Metabolic Studies. Eight-week-old male mice were placed in siliconized glass metabolic cages for 24 h. Water was provided ad libitum, food was withheld, and a standard day/night cycle was maintained. Urine was collected under a layer of mineral oil to prevent evaporation. Blood was collected from mice by cardiac puncture.
Assays for Minerals, Bone Turnover Markers, and Hormones. Serum calcium and phosphorus were measured with a Horiba Pentra 400 autoanalyzer using orthocresolphthalein complexone (OPC) (43) and phosphomolybdate (44) chemistries, respectively. Urine calcium, phosphorus, and creatinine (45) were measured on a Horiba Pentra 400. Intact serum FGF-23 (Kainos Laboratories), intact serum PTH (ALPCO), P1NP (Immunodiagnostic Systems), TRAcP 5B (Immunodiagnostic Systems), and serum sclerostin (ALPCO) were determined by ELISA. Serum creatinine, 1α,25-dihydroxyvitamin D and 24,25 dihydroxyvitamin D were measured using mass spectrometry methods as described below.
Measurement of Mouse Serum
Creatinine by Liquid-Chromatography Tandem Mass Spectrometry. Creatinine calibrators (0, 0.02, 0.05, 0.1, 0.5, 1, and 2 mg/dL) in 1% (wt/vol) BSA and phosphate buffer (0.01 M, pH 7.4) were prepared. Deuterated internal standard (creatinine-methyl d3, Sigma, 10 μL of 0.05 ng/mL solution in acetonitrile) was added to 10 μL serum. After 15 min at 25°C, 250 μL acetonitrile was added to the sample. After 10 min, samples were centrifuged at 14,000 × g. The supernatant was evaporated and samples were reconstituted in 2 mL water. A total of 15 μL of sample was injected onto an Agilent XDB-C18, 2.1 × 50-mm chromatography column (Agilent) which was developed over 7.0 min with a methanol/acetonitrile-H 2 O gradient (40-95%, vol/vol), at a flow rate of 0.25 mL/min. The aqueous and organic phases contained 1.25 mM nonafluorovaloric acid (SigmaAldrich). Mass spectrometry was performed on a 5500 mass spectrometer (AB SCIEX) using the multiple reaction-monitoring mode and Analyst 1.6.2 software for data acquisition and analysis. Q1/Q3 ion pairs were used to quantify creatinine and creatinine-methyl-d3 [114/44 daltons (Da) and 117/ 47 Da, respectively]. The limit of detection for creatinine was 0.01 mg/dL, recovery 91-102%, and interassay coefficient of variance was 6-12% depending on concentration. Measurement of Mouse Serum 24,25(OH) 2 D 3 by Liquid-Chromatography Tandem Mass Spectrometry. A total of 1.25 ng hexa-deuterated 24,25(OH) 2 D 3 internal standard solution was added to a 50 μL the experimental serum sample diluted with 450 μL stripped serum. After equilibration at 25°C for 15 min, the sample was acidified with 500 μL 0.2 N HCl. The sample was applied to a Bond-Elut cartridge (Varian Instruments), which was washed once with 2 mL 70:30 methanol/water (vol/vol), and once with 2 mL 90:10 hexane/methylene chloride (vol/vol). Vitamin D metabolites were eluted with 2 mL 90:10 hexane/isopropyl alcohol (vol/vol). Eluants were dried and derivatized with 4-phenyl-1,2,4,-triazoline-3,5-dione (PTAD) (Sigma; 250 μL of 200 μg/mL solution in acetonitrile). Derivatized vitamin D metabolites were separated by liquid chromatography at a flow rate of 0.25 mL/min on an XDB-C8, 2.1 × 50 mm column (Agilent) over 7.25 min with a methanol-H 2 O-ammonium formate (1 mM) gradient (60-95%) and quantified using mass spectrometry.
Assessment of cyp27B1 mRNA in Kidney and Proximal Tubular Cells. RNA was prepared from WT and sost KO mouse kidneys and proximal tubular (PT) cells using RNA/protein spin columns (Clontech Laboratories). An iScript RT-PCR kit (Bio-Rad Laboratories) was used to generate double-stranded DNA from RNA. Quantitative PCR (qPCR) was carried out using Lightcycler 480 SYBR Green Master I and a Roche LightCycler 480 qPCR apparatus (Roche Diagnostics). Intron-spanning qPCR primer pairs for mouse (cyp27b1) (GenBank NM_010009.2) and ribosomal protein L13A (rpl13a) (GenBank NM_009438.5) were: m cyp27b1 forward: 5′-CAGCTTCCTGGCTGAACTCT-3′; m cyp27b1 reverse: 5′-GACCATATTGGCCCGTACC-3′; m rpl13A forward: 5′-CCCTCCACCC-TATGACAAGA-3′; m rpl13A reverse: 5′-GCCCCAGGTAAGCAAACTT-3′. The iScript product was used to generate PCR products with each primer pair. QPCR data for mouse cyp27B1 was quantitated against rpl13A, using software supplied with the instrument.
Preparation of Mouse PT Cells. PT cells were prepared from SV40 T-antigen mutant tsA58 ImmortoMouse (Charles River) kidneys as previously described (46, 47) . Kidney cortex from 12-wk-old female ImmortoMouse kidneys was harvested, minced, and digested with 1% Worthington collagenase type II. Cell suspensions were filtered, suspended in 45% Percoll, and centrifuged at 27,000 × g for 15 min at 4°C. PT cells were grown on Matrigel-treated plates. Isolated PT cells were treated with 0.5 μg/mL recombinant mouse sclerostin from R&D Systems or vehicle for 24 h.
Femoral Bone Structure and Composition by Microcomputed Tomography. Bone architecture and mineralization were evaluated using ex vivo microCT (48) (49) (50) . The central portion of each femoral diaphysis (analysis region = 0.7 mm long, centered about the midshaft) and secondary spongiosa in the distal femoral metaphysis (analysis region = 6% of total bone length, beginning at 15% of total bone length measured from the epicondyles) were scanned in 70% ethanol on a μCT35 scanner (Scanco Medical) with 7-μm voxel size, an energy setting of 70 kVp, and an integration time of 300 ms.
Cryosectioning of Bone and Staining for β-Galactosidase Activity. Intact femurs were isolated from WT and sost KO mice, placed in Tissue-Tek OCT (Optimum Cutting Temperature) compound (Fisher), frozen in liquid nitrogen, and sectioned to 10-μm slices using a CM3050 S Cryostat (Leica Microsystems). Cryosectioned bone tissue was fixed in buffer (0.5% glutaraldehyde, 1.25 mM EGTA, 2 mM MgCl 2 in 1× PBS), rinsed three times in wash buffer (2 mM MgCl 2 , 0.01% deoxycholate, 0.02% Nonidet P-40, in 0.1 M sodium phosphate, pH 7.3), and stained overnight at 37°C in staining buffer (1 mg/mL X-gal (5-bromo-4-chloro-3-indolyl-b-galactopyranoside), 35 mM potassium ferrocyanide, and 35 mM potassium ferricyanide, in wash buffer) (51) .
Bone Histomorphometry. Mice were injected with calcein (10 mg/kg) 4 and 1 d before sacrifice. Femurs were fixed in 70% ethanol for 48 h and histologically prepared as previously described (52) . Briefly, thin (5 μm) sections were mounted unstained for dynamic histomorphometry, stained with Von Kossa/MacNeal's tetrachrome to highlight osteoblast surfaces, or stained with tartrate resistant acid phosphatase (TRAP)/Fast green for identification of osteoclast surfaces. Trabecular bone remodeling indices were quantified in the secondary spongiosa using OsteoMeasures software (OsteoMetrics).
Statistical Methods. Statistical differences between groups of mice were analyzed using Student's two-tailed t test assuming equal variance. P < 0.05 was regarded as statistically significant.
